Vijay Lathi

Vijay Lathi

Managing Director, Menlo Park, CA

vijay@nlvpartners.com
650-234-2700
Vijay Lathi is a Managing Director focused on information convergence and diagnostics investments. Vijay joined Sprout in 1998, was promoted to Partner in 2003, and was one of the founders of New Leaf in 2005.  Prior to focusing on information convergence, Vijay’s investment activity covered a range of healthcare technologies including HCIT, diagnostics and therapeutic platforms, and was the founding investor in both Ilypsa (sold to Amgen) and Relypsa (RLYP).
Prior to joining Sprout, Vijay was an analyst in the Healthcare Venture Capital Group at Robertson Stephens & Co. and analyst at Cornerstone Research, a consulting firm focused on financial and economic analysis for business litigation. Vijay graduated from the Massachusetts Institute of Technology and Stanford University where he received his B.S. and M.S. in Chemical Engineering, with an emphasis on the application of engineering to life science technology.

 

Board Seats and Investments

Notable Alumni Investments

Advanced Cell Diagnostics (Acquired by Bio-Techne)
ePocrates (NASDAQ: EPOC, Acquired by athenahealth)
CareDX (NASDAQ: CDNA)
Concert Pharmaceuticals (NASDAQ: CNCE)
Dice Therapeutics (Acquired by Lilly)(NASDAQ: DICE)
Focus Diagnostics (Acquired by Quest Diagnostics)
Ilypsa (Acquired by Amgen)
iRhythm Technologies (NASDAQ: IRTC)
Labcyte (Acquired by Thermo Fisher)
Oxford Immunotec (NASDAQ: OXFD)
Relypsa (NASDAQ: RLYP)